135 related articles for article (PubMed ID: 35030422)
1. Pre-administration of a carboxypeptidase inhibitor enhances tPA-induced thrombolysis in mouse microthrombi: Evidence from intravital imaging analysis.
Mathews NS; Suzuki Y; Honkura N; Sano H; Iwashita T; Urano T
Thromb Res; 2022 Feb; 210():78-86. PubMed ID: 35030422
[TBL] [Abstract][Full Text] [Related]
2. An inhibitor of activated thrombin-activatable fibrinolysis inhibitor potentiates tissue-type plasminogen activator-induced thrombolysis in a rabbit jugular vein thrombolysis model.
Nagashima M; Werner M; Wang M; Zhao L; Light DR; Pagila R; Morser J; Verhallen P
Thromb Res; 2000 May; 98(4):333-42. PubMed ID: 10822080
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of endogenous plasminogen activator-induced thrombolysis by argatroban and APC and its control by TAFI, measured in an arterial thrombolysis model in vivo using rat mesenteric arterioles.
Hashimoto M; Yamashita T; Oiwa K; Watanabe S; Giddings JC; Yamamoto J
Thromb Haemost; 2002 Jan; 87(1):110-3. PubMed ID: 11848438
[TBL] [Abstract][Full Text] [Related]
4. Fibrinolytic efficacy of Amediplase, Tenecteplase and scu-PA in different external plasma clot lysis models: sensitivity to the inhibitory action of thrombin activatable fibrinolysis inhibitor (TAFI).
Guimarães AH; Barrett-Bergshoeff MM; Criscuoli M; Evangelista S; Rijken DC
Thromb Haemost; 2006 Sep; 96(3):325-30. PubMed ID: 16953274
[TBL] [Abstract][Full Text] [Related]
5. Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis model.
Guimarães AH; Rijken DC
Thromb Haemost; 2004 Mar; 91(3):473-9. PubMed ID: 14983222
[TBL] [Abstract][Full Text] [Related]
6. A novel approach to arterial thrombolysis.
Klement P; Liao P; Bajzar L
Blood; 1999 Oct; 94(8):2735-43. PubMed ID: 10515877
[TBL] [Abstract][Full Text] [Related]
7. Endogenously generated plasmin at the vascular wall injury site amplifies lysine binding site-dependent plasminogen accumulation in microthrombi.
Brzoska T; Tanaka-Murakami A; Suzuki Y; Sano H; Kanayama N; Urano T
PLoS One; 2015; 10(3):e0122196. PubMed ID: 25806939
[TBL] [Abstract][Full Text] [Related]
8. Thrombus lysis by uPA, scuPA and tPA is regulated by plasma TAFI.
Mutch NJ; Moore NR; Wang E; Booth NA
J Thromb Haemost; 2003 Sep; 1(9):2000-7. PubMed ID: 12941043
[TBL] [Abstract][Full Text] [Related]
9. Thrombin activatable fibrinolysis inhibitor (TAFI) does not inhibit in vitro thrombolysis by pharmacological concentrations of t-PA.
Colucci M; D'Aprile AM; Italia A; Gresele P; Morser J; Semeraro N
Thromb Haemost; 2001 Apr; 85(4):661-6. PubMed ID: 11341502
[TBL] [Abstract][Full Text] [Related]
10. Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates fibrin-dependent plasmin generation on thrombin-activated platelets.
Ni R; Neves MAD; Wu C; Cerroni SE; Flick MJ; Ni H; Weitz JI; Gross PL; Kim PY
J Thromb Haemost; 2020 Sep; 18(9):2364-2376. PubMed ID: 32506822
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of carboxypeptidase U (TAFIa) activity improves rt-PA induced thrombolysis in a dog model of coronary artery thrombosis.
Björkman JA; Abrahamsson TI; Nerme VK; Mattsson CJ
Thromb Res; 2005; 116(6):519-24. PubMed ID: 16181987
[TBL] [Abstract][Full Text] [Related]
12. Changes in Activated Thrombin-Activatable Fibrinolysis Inhibitor Levels Following Thrombolytic Therapy in Ischemic Stroke Patients Correlate with Clinical Outcome.
Alessi MC; Gaudin C; Grosjean P; Martin V; Timsit S; Mahagne MH; Larrue V; Sibon I; Zuber M; Brouns R; Montaner J; Castellanos M; Donazzolo Y; Cho TH; Suissa L; Mechtouff L; Derex L; Suchon P; Mezzapesa A; Nighoghossian N
Cerebrovasc Dis; 2016; 42(5-6):404-414. PubMed ID: 27387478
[TBL] [Abstract][Full Text] [Related]
13. Tissue-type plasminogen activator transgenic rats for evaluating inhibitors of the activated form of thrombin-activatable fibrinolysis inhibitor.
Ito Y; Noguchi K; Morishima Y; Yamaguchi K
Blood Coagul Fibrinolysis; 2018 Apr; 29(3):314-321. PubMed ID: 29538006
[TBL] [Abstract][Full Text] [Related]
14. Recombinant lys-plasminogen, but not glu-plasminogen, improves recombinant tissue-type plasminogen activator-induced coronary thrombolysis in dogs.
Mehta JL; Chen L; Nichols WW; Johannesen M; Bregengård C; Hedner U; Saldeen TG
J Am Coll Cardiol; 1995 Mar; 25(3):753-60. PubMed ID: 7860925
[TBL] [Abstract][Full Text] [Related]
15. Thrombin-activable fibrinolysis inhibitor zymogen does not play a significant role in the attenuation of fibrinolysis.
Foley JH; Kim P; Nesheim ME
J Biol Chem; 2008 Apr; 283(14):8863-7. PubMed ID: 18252711
[TBL] [Abstract][Full Text] [Related]
16. Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.
Lu HR; Wu Z; Pauwels P; Lijnen HR; Collen D
J Am Coll Cardiol; 1992 May; 19(6):1350-9. PubMed ID: 1342779
[TBL] [Abstract][Full Text] [Related]
17. Inducible carboxypeptidase activity. A role in clot lysis in vivo.
Redlitz A; Nicolini FA; Malycky JL; Topol EJ; Plow EF
Circulation; 1996 Apr; 93(7):1328-30. PubMed ID: 8641019
[TBL] [Abstract][Full Text] [Related]
18. A direct oral anticoagulant edoxaban accelerated fibrinolysis via enhancement of plasmin generation in human plasma: dependent on thrombin-activatable fibrinolysis inhibitor.
Morishima Y; Honda Y
J Thromb Thrombolysis; 2019 Jul; 48(1):103-110. PubMed ID: 30972711
[TBL] [Abstract][Full Text] [Related]
19. Recombinant lys-plasminogen given before, but not after, recombinant tissue-type plasminogen activator markedly improves coronary thrombolysis in dogs: relationship of thrombolytic efficacy with parameters of fibrinolysis.
Chen LY; Nichols WW; Saldeen TG; Mehta JL
J Cardiovasc Pharmacol; 1996 Feb; 27(2):283-9. PubMed ID: 8720429
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo characterisation of the profibrinolytic effect of an inhibitory anti-rat TAFI nanobody.
Hendrickx ML; Zatloukalova M; Hassanzadeh-Ghassabeh G; Muyldermans S; Gils A; Declerck PJ
Thromb Haemost; 2014 May; 111(5):824-32. PubMed ID: 24402608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
